CoChat

Three-dimensional culture of MSCs produces exosomes with improved yield and enhanced therapeutic efficacy for cisplatin-induced acute kidney injury

Open access
Cao, Jingyuan, Wang, Bin, Tang, Taotao, Lv, Linli, Ding, Zhaoying, Li, Zuolin, Hu, Ruoyu, Wei, Qing, Shen, Anran, Fu, Yuqi, Liu, Bicheng · 2020 · Stem Cell Research & Therapy

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Abstract

Background: Exosomes derived from mesenchymal stem cells (MSC-exos) have been demonstrated with great potential in the treatment of multiple human diseases including acute kidney injury (AKI) by virtue of their intrinsic cargoes. However, there are major challenges of low yield and the lack of an established biomanufacturing platform to efficiently produce MSC-exos, thereby limiting their therapeutic application. Here, we aimed to establish a novel strategy to produce MSC-exos with a hollow fiber bioreactor-based three-dimensional (3D) culture system and evaluate the therapeutic efficacy of 3D-exosomes (3D-exos) on AKI. Methods: Mesenchymal stem cells (MSCs) were isolated from fresh human umbilical cord and cultured in two-dimensional (2D) flasks. 2 × 10 8 MSCs were inoculated into the hollow fiber bioreactor for 3D culture. The culture supernatants were collected every 1 or 2 days for isolating exosomes. Exosomes from 2D (2D-exos) and 3D cultures were characterized by transmission electron microscopy, nanoparticle tracking analysis, and western blotting analysis of exosome markers. The yield of exosomes from 2 × 10 8 MSCs seeded in 2D and 3D culture system was compared, based on protein quantification. The therapeutic efficacy of 2D-exos and 3D-exos was investigated in a murine model of cisplatin-induced AKI in vivo and in vitro. Results: 3D culture did not significantly change the surface markers of MSCs, as well as the morphology, size, and exosomal markers of 3D-exos when compared to those of 2D-exos. Compared with conventional 2D culture, the 3D culture system increased total exosome production up to 19.4-fold. 3D-exos were more concentrated in the harvested supernatants (15.5-fold) than 2D-exos, which led to a higher exosome collection efficiency of 3D culture system. In vivo,both 2D-exos and 3D-exos significantly alleviated cisplatin-induced murine AKI evidenced by improved renal function, attenuated pathological changes of renal tubules, reduced inflammatory factors, and repressed T cell and macrophage infiltration. Impressively, 3D-exos were more effective than 2D-exos. Moreover, 3D-exos were taken up by tubular epithelial cells (TECs) with improved efficiency, thereby exhibiting superior anti-inflammatory effect and improved viability of TECs in vitro. Conclusions: In summary, our findings demonstrate that the hollow fiber 3D culture system provides an efficient strategy for the continuous production of MSC-exos which has enhanced therapeutic potential for cisplatin-induced AKI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-020-01719-2

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Schematic and photograph of the 2D and 3D culture system. a The schematic of conventional 2D flask. b The general schematic of the hollow fiber bioreactor-based 3D culture system. The system was composed of a pulsatile perfusion pump, an oxygenator, a cartridge containing thousands of hollow fibers, a bottle of culture medium, and the connecting tube. c A general schematic of cross-sectional view through the bioreactor. d The photograph of our 3D culture system
Fig. 1 Schematic and photograph of the 2D and 3D culture system. a The schematic of conventional 2D flask. b The general schematic of the hollow fiber bioreactor-based 3D culture system. The system was composed of a pulsatile perfusion pump, an oxygenator, a cartridge containing thousands of hollow fibers, a bottle of culture medium, and the connecting tube. c A general schematic of cross-sectional view through the bioreactor. d The photograph of our 3D culture systemCC BY · PubMed Central
Fig. 2 3D Culture of hucMSCs. a The glucose consumption rate of 3D culture system. b The flow cytometry analysis of MSC (CD29, CD44, CD73, and CD90) and HSC (CD34 and CD45) surface markers of exfoliated cells on the 23rd and 55th days. Blue solid peaks represent the isotype controls, and the red solid peaks represent the marker indicated. c The optical micrograph of exfoliated cells in the supernatants from 3D system. Scale bar, 50 μm
Fig. 2 3D Culture of hucMSCs. a The glucose consumption rate of 3D culture system. b The flow cytometry analysis of MSC (CD29, CD44, CD73, and CD90) and HSC (CD34 and CD45) surface markers of exfoliated cells on the 23rd and 55th days. Blue solid peaks represent the isotype controls, and the red solid peaks represent the marker indicated. c The optical micrograph of exfoliated cells in the supernatants from 3D system. Scale bar, 50 μmCC BY · PubMed Central
Fig. 3 Characterization of 2D-exos and 3D-exos. a Morphology of 2D-exos and 3D-exos under TEM. Scale bar, 200 nm. b Representative NTA analysis of the particle size distribution of 2D-exos and 3D-exos. The difference between the median diameter of 2D-exos (n = 4) and 3D-exos (n = 18) was not statistically significant (p > 0.05). c The particle size distribution of 3D-exos was detected at different time points, and the median diameters of 3D-exos were 118.1–141.3 nm. d Western blotting analysis of exosomal surface markers (CD9, CD63, and Alix) of 2D-exos and 3D-exos
Fig. 3 Characterization of 2D-exos and 3D-exos. a Morphology of 2D-exos and 3D-exos under TEM. Scale bar, 200 nm. b Representative NTA analysis of the particle size distribution of 2D-exos and 3D-exos. The difference between the median diameter of 2D-exos (n = 4) and 3D-exos (n = 18) was not statistically significant (p > 0.05). c The particle size distribution of 3D-exos was detected at different time points, and the median diameters of 3D-exos were 118.1–141.3 nm. d Western blotting analysis of exosomal surface markers (CD9, CD63, and Alix) of 2D-exos and 3D-exosCC BY · PubMed Central
Fig. 4 The exosomes yield of 2D-culture and 3D-culture. a The total output of exosomes from 2 × 108 MSCs seeded in 2D and 3D culture system. b The number of particles and protein contents of 3D-exos harvested from 3D culture system at different time points
Fig. 4 The exosomes yield of 2D-culture and 3D-culture. a The total output of exosomes from 2 × 108 MSCs seeded in 2D and 3D culture system. b The number of particles and protein contents of 3D-exos harvested from 3D culture system at different time pointsCC BY · PubMed Central
Fig. 5 The therapeutic efficacy of 2D-exos and 3D-exos in cisplatin-induced AKI mice model. a Schematic diagram of the experimental design. In brief, mice were concurrently treated with PBS, 2D-exos (100 μg) or 3D-exos (100 μg) at 24 h and 48 h after cisplatin injection, and were sacrificed at 96 h after disease induction. b Effects of 2D-exos and 3D-exos on serum creatinine (n = 6–7). c Representative images of PAS staining of renal cortex. Scale bar, 50 μm. d The quantification of tubular injury based on PAS staining (n = 6–7). e Effects of 2D-exos and 3D-exos on the body weight (n = 6–7). f Representative confocal images of kidney injury molecular-1(Kim-1) in tubules. Scale bar, 25 μm. g The quantification of Kim-1+ tubules per HPF (n = 6). Data are presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Cis group, #p < 0.05, ###p < 0.001
Fig. 5 The therapeutic efficacy of 2D-exos and 3D-exos in cisplatin-induced AKI mice model. a Schematic diagram of the experimental design. In brief, mice were concurrently treated with PBS, 2D-exos (100 μg) or 3D-exos (100 μg) at 24 h and 48 h after cisplatin injection, and were sacrificed at 96 h after disease induction. b Effects of 2D-exos and 3D-exos on serum creatinine (n = 6–7). c Representative images of PAS staining of renal cortex. Scale bar, 50 μm. d The quantification of tubular injury based on PAS staining (n = 6–7). e Effects of 2D-exos and 3D-exos on the body weight (n = 6–7). f Representative confocal images of kidney injury molecular-1(Kim-1) in tubules. Scale bar, 25 μm. g The quantification of Kim-1+ tubules per HPF (n = 6). Data are presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Cis group, #p < 0.05, ###p < 0.001CC BY · PubMed Central
Fig. 6 Enhanced anti-inflammatory efficacy of 3D-exos in cisplatin-treated mice. a Real-time PCR analysis of inflammatory cytokine mRNA levels in kidney tissues (n = 6–7). b Western blotting analysis of p-p65 in kidney tissues. c Quantification of p-p65 in kidney tissues (n = 4). d Representative immunostaining images of CD68+ macrophages or CD3+ T cells in the tubulointerstitium. Scale bar, 50 μm. e Quantification of CD68+ macrophages in the tubulointerstitium (n = 6). f Quantification of CD3+ T cells in the tubulointerstitium (n = 6). g Levels of IL-6 in the mouse serum was detected by ELISA (n = 6–7). h Levels of TNF-α in the mouse serum was detected by ELISA (n = 6–7). Data are presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Cis group, #p < 0.05, ##p < 0.01
Fig. 6 Enhanced anti-inflammatory efficacy of 3D-exos in cisplatin-treated mice. a Real-time PCR analysis of inflammatory cytokine mRNA levels in kidney tissues (n = 6–7). b Western blotting analysis of p-p65 in kidney tissues. c Quantification of p-p65 in kidney tissues (n = 4). d Representative immunostaining images of CD68+ macrophages or CD3+ T cells in the tubulointerstitium. Scale bar, 50 μm. e Quantification of CD68+ macrophages in the tubulointerstitium (n = 6). f Quantification of CD3+ T cells in the tubulointerstitium (n = 6). g Levels of IL-6 in the mouse serum was detected by ELISA (n = 6–7). h Levels of TNF-α in the mouse serum was detected by ELISA (n = 6–7). Data are presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001 vs. Cis group, #p < 0.05, ##p < 0.01CC BY · PubMed Central
Fig. 7 Enhanced therapeutic efficacy of 3D-exos in cisplatin-treated TECs. a TECs took up 2D-exos and 3D-exos. DiI-positive (red) cells were observed under confocal microscope. Scale bar, 10 μm. b DiI-positive cells detecting by flow cytometry. Blue solid peak represents cisplatin-treated TECs internalizing DiI-labeled 2D-exos, and the green solid peak represents cisplatin-treated TECs internalizing DiI-labeled 3D-exos. c The uptake efficiency of 2D-exos and 3D-exos. d Real-time PCR analysis of inflammatory cytokine mRNA levels in TECs (n = 4). e CCK-8 assay in TECs (n = 6). Data are presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, vs. Cis group, #p < 0.05, ##p < 0.01, ###p < 0.001
Fig. 7 Enhanced therapeutic efficacy of 3D-exos in cisplatin-treated TECs. a TECs took up 2D-exos and 3D-exos. DiI-positive (red) cells were observed under confocal microscope. Scale bar, 10 μm. b DiI-positive cells detecting by flow cytometry. Blue solid peak represents cisplatin-treated TECs internalizing DiI-labeled 2D-exos, and the green solid peak represents cisplatin-treated TECs internalizing DiI-labeled 3D-exos. c The uptake efficiency of 2D-exos and 3D-exos. d Real-time PCR analysis of inflammatory cytokine mRNA levels in TECs (n = 4). e CCK-8 assay in TECs (n = 6). Data are presented as mean ± SD, *p < 0.05, **p < 0.01, ***p < 0.001, vs. Cis group, #p < 0.05, ##p < 0.01, ###p < 0.001CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 264

Metadata

Authors
Cao, J., Wang, B., Tang, T., Lv, L., Ding, Z., Li, Z., Hu, R., Wei, Q., Shen, A., Fu, Y., & Liu, B.
Affiliations
Zhongda Hospital Southeast University (CN)
Venue
Stem Cell Research & Therapy
Published
2020-05-27
Volume
11
Issue
1
Pages
206-206
ISSN
1757-6512 (ISSN-L)
OpenAlex
W3032250687
Cited by
264
References
51
Citations by year
2026: 26 · 2025: 64 · 2024: 48 · 2023: 51 · 2022: 45 · 2021: 26 · 2020: 4
FWCI
10.17
Type
journal article
Language
en
Open access
Licence
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81720108007, 81670696)
  • National Key Research and Development Program (2018YFC1314000)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Chemotherapy-induced organ toxicity mitigation
Keywords
mesenchymal stem cells, exosomes, 3D cell culture, hollow fiber bioreactor, exosome yield, cisplatin-induced acute kidney injury, renal tubular epithelial cells, exosome uptake, renal inflammation, T cell infiltration, macrophage infiltration, exosome therapy, umbilical cord-derived stem cells, tubular regeneration, renal fibrosis
MeSH terms
Animals, Cisplatin, Humans, Umbilical Cord, Mice, Exosomes, Acute Kidney Injury, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Three-dimensional culture of MSCs produces exosomes with improved yield and enhanced therapeutic efficacy for cisplatin-induced acute kidney injury. https://app.cochat.ai/papers/10.1186/s13287-020-01719-2
The paper
Cao, J., Wang, B., Tang, T., Lv, L., Ding, Z., Li, Z., Hu, R., Wei, Q., Shen, A., Fu, Y., & Liu, B. (2020). Three-dimensional culture of MSCs produces exosomes with improved yield and enhanced therapeutic efficacy for cisplatin-induced acute kidney injury. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-020-01719-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.